Myriad Genetics (DE:MYD)
FRANKFURT:MYD

Myriad Genetics Stock Price & Analysis

0 Followers

MYD Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€15.51 - €27.30
Previous Close€18.59
Volume0.00
Average Volume (3M)198.00
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$193.20M
Total Debt (Recent Filing)$137.30M
Price to Earnings (P/E)N/A
Beta1.85
Next EarningsFeb 23, 2023
EPS Estimate-€0.14
Dividend YieldN/A
EPS (TTM)N/A
Shares Outstanding81,033,816
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume12
30 Day Avg. Volume198
Price to Book (P/B)5.24
Price to Sales (P/S)2.41
Price to Cash Flow (P/CF)92.10
P/FCF Ratio-11.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside13.96% Upside
Rating ConsensusHold
AlphaN/A
Number of Analyst Covering4


Financials


MYD FAQ

What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest stock price was €15.51 and its highest was €27.30 in the past 12 months.
    What is Myriad Genetics’s market cap?
    Currently, no data Available
    When is Myriad Genetics’s upcoming earnings report date?
    Myriad Genetics’s upcoming earnings report date is Feb 23, 2023 which is in 76 days.
      How were Myriad Genetics’s earnings last quarter?
      Myriad Genetics released its earnings results on Nov 01, 2022. The company reported -€0.181 earnings per share for the quarter, missing the consensus estimate of -€0.038 by -€0.143.
        Is Myriad Genetics overvalued?
        According to Wall Street analysts Myriad Genetics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Myriad Genetics pay dividends?
          Myriad Genetics pays a Notavailable dividend of €1.67 which represents an annual dividend yield of N/A. Myriad Genetics’s last Notavailable dividend payment was on Jun 30, 2009. Myriad Genetics’s upcoming ex-dividend date is Jun 15, 2009
            What is Myriad Genetics’s EPS estimate?
            Myriad Genetics’s EPS estimate is -€0.14.
              How many shares outstanding does Myriad Genetics have?
              Currently, no data Available
              What happened to Myriad Genetics’s price movement after its last earnings report?
              Myriad Genetics reported an EPS of -€0.181 in its last earnings report, missing expectations of -€0.038. Following the earnings report the stock price went up 0.432%.
                Which hedge fund is a major shareholder of Myriad Genetics?
                Among the largest hedge funds holding Myriad Genetics’s share is Glenview Capital Management LLC. It holds Myriad Genetics’s shares valued at 28M.

                  ---

                  Myriad Genetics Stock Smart Score

                  1
                  Underperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -22.02%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -8.20%
                  Trailing 12-Months
                  Asset Growth
                  -9.27%
                  Trailing 12-Months
                  The Myriad Genetics Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Myriad Genetics

                  Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Recursion Pharmaceuticals
                  Immunovant
                  Celldex
                  Agios Pharma
                  Prime Medicine, Inc.

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis